Infectious Disease Diagnostics – Products

Mologic has announced that its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics initiative launched by the U.S. National Institutes of Health. The initiative aims to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing.

Thermo Fisher Scientific and Artificial have announced a collaboration to develop an integrated and comprehensive software automation platform for Thermo Fisher’s standardized COVID-19 Testing Platform. The integration will result in increased testing throughput and support global healthcare initiatives.

Pioneering British biotech MicrosensDx has announced that its RapiPRO™ LAMP SARS-CoV-2 test has received CE Certification.

Promega Corporation has released XpressAmp™ Direct Amplification Reagents that facilitate RNA extraction-free sample preparation that is automation-friendly. With this innovation, laboratories testing for COVID-19 have a new tool that enables them to skip the potentially bottlenecked RNA extraction step of the workflow and move directly to polymerase chain reaction (PCR) amplification.

PCR Biosystems have launched a range of IsoFast™ Bst Polymerase reagents for rapid, robust and sensitive DNA and RNA amplification.

PerkinElmer, Inc., has announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec).

PerkinElmer, Inc. has announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit.

Company expands SARS-CoV-2 assay portfolio with RT-PCR and next generation sequencing solutions to identify mutations associated with SARS-CoV-2 variants.

La Jolla Institute for Immunology (LJI) has announced that it has signed a licensing agreement with Leinco Technologies, Inc. Leinco also provides custom manufacturing services to the diagnostic and biopharmaceutical industries to leverage proprietary COVID-19 antibodies developed at LJI.

Nonacus today announced the commercial launch of a new service for Whole Genome Sequencing of SARS-CoV-2, developed to enable the UK government’s Test-To-Release scheme. Assay development for the new service was funded by a grant from Innovate UK, the UK’s innovation agency.